BioSpace News Archive

Anika Therapeutics, Inc. announced that on December 1, 2021, Anika granted non-statutory stock options covering an aggregate of 1,069 shares of common stock and restricted stock units covering an aggregate of 468 shares of common stock to 1 newly hired non-executive employee.

Concord Medical Services Holdings Limited today announced its unaudited consolidated financial results for the six months ended June 30, 2021[1].

Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.

In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board.

Kraig Biocraft Laboratories, Inc. announces today that its spider silk was featured in a new episode of the BBC Earth’s “Inspired By Nature” series.

Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalized myasthenia gravis (gMG).

CASI Pharmaceuticals, Inc. today announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for BI-1206.

StageZero Life Sciences, Ltd., a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to report that shareholders approved at a special meeting the issuance of 8,000,000 common shares of the Company to Health Clinics Limited.

Avicanna Inc. announced today it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

Centene Corporation (NYSE: CNC) today will host its investor day virtually and outline its 2022 financial guidance as well as provide details of its Value Creation Plan, designed to deliver enhanced earnings growth and create long-term shareholder value.